专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130292337A1 POLYMERIC IRON CHELATING AGENT 有权
标题翻译：聚合铁焊接剂
公开(公告)号：US20130292337A1
公开(公告)日：2013-11-07
申请号：US13979230
申请日：2012-01-12
申请人： Yuzo Nishida , Yutaka Kohgo , Katsuya Ikuta , Katsunori Sasaki
发明人： Yuzo Nishida , Yutaka Kohgo , Katsuya Ikuta , Katsunori Sasaki
IPC分类号： C02F1/28
CPC分类号： C02F1/286 , A61K31/722 , A61K31/731 , A61M1/3687 , C02F1/52 , C02F1/64 , C02F1/683 , C02F2101/203 , C02F2303/16 , C02F2303/18 , C08B37/003 , C08L5/08
摘要： Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH3, —CH2—CH3, —CH2—C6H5, —CH2—C5H4N or —CH2—COOH and B represents —CH2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.
摘要翻译：公开了具有聚合物主链和通过-NH-CH 2键连接到聚合物主链的芳环的水不溶性聚合铁螯合剂，其中芳环具有一个或两个羟基形式的第一官能团，位于相对于第一官能团的邻位置的一个或两个第二官能团; 并且其中第二官能团是-OH，-COOH或由式（I）表示的基团，其中A表示-CH 3，-CH 2 -CH 3，-CH 2 -C 6 H 5，-CH 2 -C 5 H 4 N或-CH 2 -COOH，B表示 -CH 2 -COOH。本发明的水不溶性聚合铁螯合剂具有能够选择性螯合铁离子，特别是生物不稳定的铁，并且不溶于水的优点，此外还不包括在体内代谢过程中。

2. 发明授权

US08623661B2 Iron chelating agent, method for producing same, method for determining amount of iron ions and method for trapping iron ions 有权
标题翻译：铁螯合剂，其制造方法，铁离子的测定方法和铁离子的捕获方法
公开(公告)号：US08623661B2
公开(公告)日：2014-01-07
申请号：US13120126
申请日：2009-09-18
申请人： Yutaka Kohgo , Katsuya Ikuta , Katsunori Sasaki , Yuzo Nishida
发明人： Yutaka Kohgo , Katsuya Ikuta , Katsunori Sasaki , Yuzo Nishida
IPC分类号： G01N33/20 , C07C229/14 , C07D233/64 , C07C229/26
CPC分类号： A61K31/198 , A61K31/4172
摘要： The present invention provides an iron chelating agent which can selectively chelate iron ions. The iron chelating agent of the present invention includes a compound represented by the following formula (1) or a salt thereof (wherein, ring Z represents an aromatic hydrocarbon ring or an aromatic heterocyclic ring; R1 represents an alkylene group; R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group or a group having chelating ability; and the total coordination number of the groups represented by R2 and R3 is 1 or 2.)
摘要翻译：本发明提供了一种可以选择性螯合铁离子的铁螯合剂。本发明的铁螯合剂包括由下式（1）表示的化合物或其盐（其中，环Z表示芳族烃环或芳香族杂环; R 1表示亚烷基; R 2和R 3各自独立地表示代表氢原子，烃基或具有螯合能力的基团;由R 2和R 3表示的基团的总配位数为1或2）

3. 发明授权

US09796605B2 Polymeric iron chelating agent 有权
公开(公告)号：US09796605B2
公开(公告)日：2017-10-24
申请号：US13979230
申请日：2012-01-12
申请人： Yuzo Nishida , Yutaka Kohgo , Katsuya Ikuta , Katsunori Sasaki
发明人： Yuzo Nishida , Yutaka Kohgo , Katsuya Ikuta , Katsunori Sasaki
IPC分类号： B01D21/01 , B03D3/00 , C02F1/52 , B01D15/00 , B01J20/00 , C08B37/08 , C02F1/28 , C02F1/64 , A61M1/36 , A61K31/731 , A61K31/722 , C08L5/08 , C02F1/00 , B01D21/00 , C02F1/42 , B01J49/00 , C02F1/68 , C02F101/20
CPC分类号： C02F1/286 , A61K31/722 , A61K31/731 , A61M1/3687 , C02F1/52 , C02F1/64 , C02F1/683 , C02F2101/203 , C02F2303/16 , C02F2303/18 , C08B37/003 , C08L5/08
摘要： Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH3, —CH2—CH3, —CH2—C6H5, —CH2—C5H4N or —CH2—COOH and B represents —CH2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.

4. 发明授权

US08491887B2 Anticancer therapy by transplanting vascular endothelial progenitor cells 失效
标题翻译：通过移植血管内皮祖细胞进行抗癌治疗
公开(公告)号：US08491887B2
公开(公告)日：2013-07-23
申请号：US12600530
申请日：2008-05-19
申请人： Yusuke Mizukami , Yutaka Kohgo , Kazumasa Nakamura
发明人： Yusuke Mizukami , Yutaka Kohgo , Kazumasa Nakamura
IPC分类号： A61K35/12
CPC分类号： A61K35/44
摘要： An anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor is provided. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable to evade rejection. When autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and used as endothelial progenitor cells.
摘要翻译：提供使用自体细胞等的抗癌疗法，其诱导癌症消退或具有良好的药物递送效果并导致肿瘤中的缺氧区域的减少或撤出。通过静脉内或其它方法移植内皮祖细胞导致肿瘤生长抑制，血管密度增加，血管直径增大，以及肿瘤中缺氧区的减少。可以实现内皮祖细胞的同种异体移植以确保用于治疗的细胞，然而，期望从癌症患者自体移植内皮祖细胞以逃避排斥。当使用自体细胞时，将单核细胞与患者的外周血液或骨髓分离，并使用含有细胞因子如VEGF的内皮分化培养基进行培养以获得贴壁细胞，然后将其收集并用作内皮祖细胞。

5. 发明授权

US10792315B2 Intestinal protectant 有权
公开(公告)号：US10792315B2
公开(公告)日：2020-10-06
申请号：US13639206
申请日：2011-03-28
申请人： Yutaka Kohgo , Mikihiro Fujiya , Nobuhiro Ueno , Syuichi Segawa , Naoyuki Kobayashi
发明人： Yutaka Kohgo , Mikihiro Fujiya , Nobuhiro Ueno , Syuichi Segawa , Naoyuki Kobayashi
IPC分类号： A61K35/747 , A61K33/42 , A23L2/52 , A23L33/16 , A23L33/10 , A23L33/135
摘要： The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.

6. 发明授权

US5843677A Method of assaying asialoglycoprotein receptor and assay reagent therefor 失效
标题翻译：测定脱唾液酸糖蛋白受体的方法及其试剂
公开(公告)号：US5843677A
公开(公告)日：1998-12-01
申请号：US722153
申请日：1996-10-18
申请人： Yoshiro Niitsu , Yutaka Kohgo , Junji Kato , Hirokazu Yago , Hisashi Hanada , Koji Ushizawa
发明人： Yoshiro Niitsu , Yutaka Kohgo , Junji Kato , Hirokazu Yago , Hisashi Hanada , Koji Ushizawa
IPC分类号： G01N33/53 , G01N33/531 , G01N33/543 , G01N33/577 , G01N33/68 , C07K16/28
CPC分类号： G01N33/68
摘要： The present invention is directed to a method of immunoassay of asialoglycoprotein receptors (AGPR) by bringing a specimen into contact with a monoclonal antibody that recognizes AGPR, wherein the pH of a diluted specimen solution is adjusted from 5 to 7 or phenol is added to a solution of an enzyme-labeled antibody. This method is excellent in the sensitivity and accuracy of AGPR assay and can be applied also to the screening of hepatopathy remedies.
摘要翻译： PCT No.PCT / JP95 / 00770 Sec。 371日期：1996年10月18日 102（e）日期1996年10月18日PCT提交1995年4月19日PCT公布。 WO95 / 29403 PCT出版物日期：1995年11月2日本发明涉及一种通过使样品与识别AGPR的单克隆抗体接触的免疫测定来测定脱唾液酸糖蛋白受体（AGPR）的方法，其中将稀释样品溶液的pH调节为5〜7或将苯酚加入到酶标记抗体的溶液中。该方法在AGPR测定的灵敏度和准确性方面优异，也可用于筛查肝病治疗。

7. 发明授权

US08951795B2 Revascularization cells derived from mononuclear cells, and method of inducing differentiation thereof 有权
标题翻译：来自单核细胞的血运重建细胞及其诱导分化的方法
公开(公告)号：US08951795B2
公开(公告)日：2015-02-10
申请号：US13138835
申请日：2010-03-29
申请人： Yusuke Mizukami , Junpei Sasajima , Yoshiaki Sugiyama , Kazuya Sato , Yutaka Kohgo
发明人： Yusuke Mizukami , Junpei Sasajima , Yoshiaki Sugiyama , Kazuya Sato , Yutaka Kohgo
IPC分类号： C12N5/00 , C12N5/078 , A61K35/12
CPC分类号： C12N5/0634 , A61K2035/124 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/145 , C12N2501/165 , C12N2501/22 , C12N2501/26
摘要： The present invention relates to a method of safely and simply inducing differentiation of mononuclear cells into cells that promote neovascular stabilization and maturation, and lead to recovering from ischemia or tissue repair. The cells according to the present invention are obtained by inducing differentiation of a mononuclear cell by culturing the mononuclear cell in a medium (particularly a serum-free medium) containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), and collecting a cell population expressing CD11b.
摘要翻译：本发明涉及将单核细胞分化成促进新生血管稳定和成熟的细胞的方法，并且导致从缺血或组织修复中恢复。根据本发明的细胞是通过在含有选自血管内皮生长因子（VEGF），碱性成纤维细胞生长因子（VEGF）的一种或多种的介质（特别是无血清培养基）中培养单核细胞来诱导单核细胞的分化来获得的。（bFGF），血小板生成素（TPO），粒细胞集落刺激因子（G-CSF）和FMS样酪氨酸激酶3配体（FLT3L），并收集表达CD11b的细胞群。

8. 发明申请

US20130171118A1 INTESTINAL PROTECTANT 审中-公开
公开(公告)号：US20130171118A1
公开(公告)日：2013-07-04
申请号：US13639206
申请日：2011-03-28
申请人： Yutaka Kohgo , Mikihiro Fujiya , Nobuhiro Ueno , Syuichi Segawa , Naoyuki Kobayashi
发明人： Yutaka Kohgo , Mikihiro Fujiya , Nobuhiro Ueno , Syuichi Segawa , Naoyuki Kobayashi
IPC分类号： A61K35/74 , A23L1/30 , A61K33/42
摘要： The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.
摘要翻译：本发明提供包含多磷酸或其药学上可接受的盐作为活性成分的肠道保护剂。

9. 发明申请

US20120100610A1 REVASCULARIZATION CELLS DERIVED FROM MONONUCLEAR CELLS, AND METHOD OF INDUCING DIFFERENTIATION THEREOF 有权
标题翻译：从单核细胞衍生的再分化细胞和诱导其分化的方法
公开(公告)号：US20120100610A1
公开(公告)日：2012-04-26
申请号：US13138835
申请日：2010-03-29
申请人： Yusuke Mizukami , Junpei Sasajima , Yoshiaki Sugiyama , Kazuya Sato , Yutaka Kohgo
发明人： Yusuke Mizukami , Junpei Sasajima , Yoshiaki Sugiyama , Kazuya Sato , Yutaka Kohgo
IPC分类号： C12N5/071 , C12N5/077 , C12N5/078
CPC分类号： C12N5/0634 , A61K2035/124 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/145 , C12N2501/165 , C12N2501/22 , C12N2501/26
摘要： The present invention relates to a method of safely and simply inducing differentiation of mononuclear cells into cells that promote neovascular stabilization and maturation, and lead to recovering from ischemia or tissue repair. The cells according to the present invention are obtained by inducing differentiation of a mononuclear cell by culturing the mononuclear cell in a medium (particularly a serum-free medium) containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), and collecting a cell population expressing CD11b.
摘要翻译：本发明涉及将单核细胞分化成促进新生血管稳定和成熟的细胞的方法，并且导致从缺血或组织修复中恢复。根据本发明的细胞是通过在含有选自血管内皮生长因子（VEGF），碱性成纤维细胞生长因子（VEGF）的一种或多种的介质（特别是无血清培养基）中培养单核细胞来诱导单核细胞的分化来获得的。（bFGF），血小板生成素（TPO），粒细胞集落刺激因子（G-CSF）和FMS样酪氨酸激酶3配体（FLT3L），并收集表达CD11b的细胞群。

10. 发明申请

US20100143311A1 ANTICANCER THERAPY BY TRANSPLANTING VASCULAR ENDOTHELIAL PROGENITOR CELLS 失效
标题翻译：通过移植血管内皮祖细胞治疗的抗生素治疗
公开(公告)号：US20100143311A1
公开(公告)日：2010-06-10
申请号：US12600530
申请日：2008-05-19
申请人： Yusuke Mizukami , Yutaka Kohgo , Kazumasa Nakamura
发明人： Yusuke Mizukami , Yutaka Kohgo , Kazumasa Nakamura
IPC分类号： A61K35/12 , A61P35/04
CPC分类号： A61K35/44
摘要： It is intended to provide anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable in order to evade rejection. When the autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and advantageously used as endothelial progenitor cells.
摘要翻译：本发明旨在提供使用自体细胞等的抗癌治疗，其诱导癌症消退或具有良好的药物递送作用并导致肿瘤中缺氧区域的减少或撤出。通过静脉内或其它方法移植内皮祖细胞导致肿瘤生长抑制，血管密度增加，血管直径增大，以及肿瘤中缺氧区的减少。可以实现内皮祖细胞的同种异体移植以确保用于治疗的细胞，然而，为了逃避排斥反应，来自癌症患者的内皮祖细胞的自体移植将是期望的。当使用自体细胞时，将单核细胞与患者的外周血液或骨髓分离，并使用含有细胞因子如VEGF的内皮分化培养基进行培养以获得贴壁细胞，然后可以将其收集并有利地用作内皮祖细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式